UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy
Wedbush reiterated its Outperform rating on Xoma (NASDAQ: XOMA) and raised its price target from $4 to $5.
Wedbush commented, "Xoma announced that Gevokizumab demonstrated initial clinical efficacy as a treatment candidate for severe inflammatory acne. Interim results from 92 of 125 enrolled patients to date showed that the higher of two doses (0.2 and 0.6 mg/kg) of Gevokizumab demonstrated a consistent mean reduction from an average baseline of 31 inflammatory lesions to 19 through Day 84 with statistically significant reduction on Day 42 (p=0.077 based on 80% power to achieve p<0.10)."
Xoma closed at $2.77 on Friday.
Latest Ratings for XOMA
|May 2015||Credit Suisse||Assumes||Neutral|
|Mar 2015||Ladenburg Thalmann||Upgrades||Neutral||Buy|
|Nov 2014||Ladenburg Thalmann||Downgrades||Buy||Neutral|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.